• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Surface Oncology Pauses CD39 Program, Slashes Workforce by 20%

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Nov 02, 2022 at 10:52: PM
via Massachusetts-based Surface Oncology will pause the development of its CD39-targeted antibody SRF617 and cut around 20% of its workforce to focus on its lead anti-IL-27 program SRF388, the company announced Wednesday.

article source
 




Top Bottom
Back
Quote